Skip to main content
ARECOR THERAPEUTICS PLC logo

ARECOR THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AREC ISIN · GB00BMWLM973 LEI · 98450093D12I3A8DDD58 IL Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2024-01-23 M&A Activity
Country GB United Kingdom
Listing IL AREC

About ARECOR THERAPEUTICS PLC

https://arecor.com/

Arecor Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing enhanced therapeutic medicines. The company utilizes its proprietary Arestat® technology platform, a formulation science designed to improve the properties of proteins and peptides, enabling superior drug product profiles. Arecor's business model involves two approaches: developing an internal portfolio of proprietary products and partnering with pharmaceutical and medtech companies to enhance their therapeutic offerings. The company's in-house development pipeline is primarily focused on advancing treatments for diabetes and other cardiometabolic diseases, including next-generation insulin candidates.

Recent filings

Filing Released Lang Actions
Arecor announces update on INBRX-101
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 6673A' and is dated '23 January 2024'. It details a significant corporate event: the acquisition of Inhibrx's therapy (INBRX-101), which incorporates Arecor's technology, by Sanofi. This is a material announcement concerning corporate activity and potential future financial implications (milestone payments, technology access fees). Since it is a formal announcement distributed via RNS (the news service of the London Stock Exchange) and concerns a major transaction/update that doesn't fit neatly into specific financial report categories (like 10-K, ER, or IR), it falls best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous regulatory announcements. Given the content is a news release about a transaction, RNS is the most appropriate classification.
2024-01-23 English
Arecor granted key European patent
Environmental & Social Information Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content announces a specific corporate event: the granting of a key European patent for insulin products. This is a material, non-financial announcement typically disseminated via regulatory news services. Since the document is short and functions as an announcement of a specific event (patent grant) rather than a comprehensive report (like 10-K or IR), it fits best under the general Regulatory Filings category (RNS) as it is a direct regulatory news service release, although it relates to Intellectual Property. However, given the specific nature of the announcement (patent grant, IP portfolio updates), it is a specific type of regulatory disclosure. Since there is no specific code for 'Intellectual Property Announcement' and it is not a Legal Proceeding Report (LTR), the most appropriate general regulatory category is RNS, as it is explicitly sourced from RNS and is a general regulatory update.
2024-01-18 English
Expansion of specialty hospital collaboration
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated 08 January 2024. It announces an 'expansion of existing specialty hospital formulation collaboration' and contains contact information typical of a regulatory news service release. The presence of the RNS header, the explicit mention of 'This information is provided by RNS, the news service of the London Stock Exchange,' and the overall structure strongly indicate this is a general regulatory announcement. Since it is not a specific financial report (like 10-K, IR, ER) or a specific corporate action (like DIV, DIRS, CAP), the most appropriate classification is the general regulatory filing category.
2024-01-08 English
Appointment of SVP for Tetris Pharma Ltd
Board/Management Information Classification · 98% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content announces the appointment of a new Senior Vice President and General Manager, which falls under changes in senior management. This directly corresponds to the Board/Management Information category (MANG). Although it is an RNS announcement, the specific content is about management change, making MANG a more precise classification than the general RNS fallback.
2024-01-03 English
Agreement with global medical products company
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and is dated December 4, 2023. It announces a significant business event: 'ARECOR SIGNS CO-DEVELOPMENT AND EXCLUSIVE LICENCE OPTION AGREEMENT WITH LEADING GLOBAL MEDICAL PRODUCTS COMPANY'. The text explicitly states, 'This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR")' and concludes with boilerplate text from RNS, the news service of the London Stock Exchange. This structure is characteristic of a general regulatory news service announcement, which fits the definition of 'Regulatory Filings' (RNS) as a broad category for official, non-standardized market disclosures, especially when the content is a strategic agreement rather than a periodic financial report (like 10-K or IR) or a specific transaction report (like DIV or DIRS). Since it is not a specific type like a dividend notice, earnings release, or director dealing, RNS is the most appropriate classification.
2023-12-04 English
Arecor Continues Collaboration with Lilly
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 9702U' and is dated November 29, 2023. It announces a collaboration agreement between Arecor Therapeutics PLC and Eli Lilly and Company regarding formulation development. The text explicitly states, 'This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").' Furthermore, the footer mentions, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and content strongly indicate a general regulatory news service announcement, which aligns best with the 'Regulatory Filings' category (RNS), as it is not a specific financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Given the RNS header and context, RNS is the most appropriate classification.
2023-11-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.